ARTICLE | Clinical News
Brilacidin: Phase II started
June 27, 2016 7:00 AM UTC
Cellceutix began an observer-blind Phase II trial to evaluate 3 dose levels of once-daily brilacidin given via retention enema for 6 weeks in 18 patients. ...
Cellceutix began an observer-blind Phase II trial to evaluate 3 dose levels of once-daily brilacidin given via retention enema for 6 weeks in 18 patients. ...